E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. - Wikidata - wikimedia - TriplyDB

E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

http://www.wikidata.org/entity/Q41931667

about

An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin Ionizing radiation induces heritable disruption of epithelial cell interactions The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression.E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions E-Cadherin and beta-Catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases Aberrant E-cadherin staining patterns in invasive mammary carcinoma Ductal barriers in mammary epithelium Adhesion in mammary development: novel roles for E-cadherin in individual and collective cell migration E-cadherin-catenin cell-cell adhesion complex and human cancer Correlation of Snail expression with histological grade and lymph node status in breast carcinomas E-Cadherin Suppresses Cellular Transformation by Inhibiting β-Catenin Signaling in an Adhesion-Independent Manner Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.Clinicopathological study of male breast carcinoma: 24 years of experience.Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression.Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells.E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.Systems biology and genomics of breast cancer.Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics Lobular breast cancer: molecular basis, mouse and cellular models.Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.Issues in the interpretation of breast core biopsies.Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors Lobular neoplasia: frequency and association with other breast lesions.Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology Classification of ductal carcinoma in situ by gene expression profiling.Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression Molecular drivers of lobular carcinoma in situ.E- and N-cadherin distribution in developing and functional human teeth under normal and pathological conditions.Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation.Genetic characterization of breast cancer and implications for clinical management Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.E-Cadherin as a diagnostic biomarker in breast cancer.

P2860

Q21195234-7517F998-40D6-4276-8450-1976C4FAD14D Q21296833-D37D709A-BA52-4BBC-BF7E-943F448D7D24 Q24535378-A0B5161D-A4E2-4C38-A75F-DFD0FEBBDF7C Q24653604-0C85AE2D-6539-432E-8DD4-49ABB7ED0DA5 Q24685810-0DC56B04-55FE-4768-90DC-914033DA54AF Q24801633-171A1714-5F2E-4211-8BBF-F1BDB703DD0E Q24802136-761639A7-F1B0-4F12-909B-08537C3226C3 Q24802857-A3669B91-E441-4AC2-A950-D4E362D195A3 Q24811225-CD0E479F-FDA3-4263-B543-25AD4F334394 Q24815807-8BDBF35C-C0B9-49FF-969F-4AE3F98EDAF1 Q27023960-21F16516-815D-49AB-8A24-5F3C20D9DC4D Q28087050-4D902746-2CBC-4FF2-92C9-10DAF569703E Q28142886-6D83D04D-A47F-40FF-982E-F45152A537FE Q28206944-981B0AC1-A5BF-4EEF-A468-0E2AF933D057 Q28972449-2D1AEBAD-C6FF-4152-9309-F74C8A509F2D Q33723770-2186716C-32B9-4F79-AD3E-72B865F4F4CB Q33738278-5422E36B-DB80-4536-9934-D13DA286F602 Q33887440-3D0A5721-E0E9-4141-8BAA-3687DDBFC2C5 Q33918637-C51EAAE4-1114-4F91-A1F3-FA0813D26B2F Q34023759-9E645CEF-4B95-4BAE-88A6-87AC69E4B67A Q34440049-AA10DED2-3418-4330-84E9-22993F4A0EBA Q34497064-C1C43C74-6167-404A-86E7-C19183E65C58 Q34576377-FA5BC3EF-1428-4870-A41D-CE9957CA684E Q34990925-A9247881-95A7-4AF0-A804-5A2605D63942 Q35025646-4584C9B8-6C14-4451-BC26-E7A269195448 Q35059856-20F46813-B873-4590-808C-2FD5C33D6451 Q35142784-C7758929-AC47-4C0E-B82F-AFE44F00B58E Q35190201-10BAB2AA-D352-4D0E-B261-4B3F608033D3 Q35204472-6B702207-6CD9-460A-83DC-5C211EB69AB8 Q35207074-713A425C-313D-48E0-B7D8-4883C0B000A6 Q35287180-2C63BE3D-134C-4953-BEB5-0E13A5A4B0B5 Q35591389-13794B4C-E11F-46E1-A9D4-7E881C05AD06 Q35605885-C8C76AD5-685B-4216-B434-52866C7C0D3A Q35636561-85D656AA-250B-4EB8-ADDF-9ECEC9948E74 Q35676504-F9EC97FE-64FE-4AC2-A2EF-1F92B197A229 Q35747985-488BB9F4-CEDD-4FEE-9ED2-3889F5490643 Q35787755-B17D310F-F9A5-4F21-9670-3F10C84C5B47 Q35832016-A1439B0B-5540-4E61-A0C0-7426294848FA Q35846896-BB54C6E2-9A02-429E-9646-3DF4423A1A1A Q35915812-615A4389-C6D7-4BF6-9605-C42B3A0D7FE2

P2860

E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

http://www.wikidata.org/entity/Q41931667

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

E-cadherin inactivation in lob ...... early event in tumorigenesis.

@en

type

label

E-cadherin inactivation in lob ...... early event in tumorigenesis.

@en

prefLabel

E-cadherin inactivation in lob ...... early event in tumorigenesis.

@en

P1433

Q41931667-3B4E3F58-9CAF-4976-A2C2-F279D9B3D71A

P1476

Q41931667-331882C4-3A4B-4A92-ACA4-CA014D81C6D8

P2093

Q41931667-295CC066-883A-4502-9116-4D3946583BDE

Q41931667-4A6055F1-CEA0-4702-9745-BB87CD551F47

Q41931667-4EDF1F8E-A6BA-45DB-8446-5D751217425B

Q41931667-9C9F582A-D561-4C63-ACF2-772082976A3E

Q41931667-E2139CE0-CD83-4F97-BD55-9E946B1D305E

Q41931667-E26881C6-E041-4B44-B3E6-A46202B57F84

Q41931667-E73502A8-1489-4E92-B31F-DE16CEB78489

Q41931667-FF5FCF46-D3E2-4410-84A3-D559A8B1A5B8

P2860

Q41931667-19DC1F85-1F46-4527-9342-E2791911CF33

Q41931667-255EF46F-33C5-46DD-978A-7931122B3CC1

Q41931667-43DCD1FB-DC8F-4BB3-B962-ECD2B967390A

Q41931667-47B31748-F943-4160-A5AB-D2573AFDA2AC

Q41931667-59572A20-16B6-458A-ABF8-7ACC157AFB6D

Q41931667-69C8ABF1-D718-4490-ABC7-D1250AB29D0C

Q41931667-9B2B287B-2F9A-45B3-8E69-FC3494AE59EC

Q41931667-C8806B7D-24DA-4A96-A3C7-262795497897

Q41931667-D2BA3BFF-7CF7-448E-848E-82E1C59AA079

Q41931667-D8F4DA74-38B6-4ABF-AA63-F813D889EBB7

P2888

Q41931667-6463B892-6957-4452-BC92-471475E55B52

P304

Q41931667-5ED639FE-EFE9-4BDB-857A-EFBCF6BE55BC

P31

Q41931667-30A9899D-FEF9-4C1A-B510-7E658818D86E

P356

Q41931667-004FC81D-3981-42A7-B3AE-C596E29D0082

P407

Q41931667-2584F1A4-654E-4F7F-8E62-177B647F8CF4

P433

Q41931667-9ED9C102-40E2-49C5-8B99-A01FA321F795

P478

Q41931667-E6727717-1545-40E1-BF7D-92CF8D3EBC1C

P50

Q41931667-A08446DA-B194-4F85-9582-530564F3DE47

P577

Q41931667-BB1A6A99-F716-482D-B15F-240A8DAA862B

P5875

Q41931667-1DC73595-5767-4CB7-8A6F-82A2F15F46BC

P6179

Q41931667-3120D514-7800-431E-AA05-6B4376332DCC

P698

Q41931667-0B2A8E9F-5E30-4B23-A6CD-EDCA705A811C

P932

Q41931667-CE4B3575-4E4A-4CDA-B464-BD8DF66D80DC

P356

P1433

British Journal of Cancer

P1476

E-cadherin inactivation in lob ...... early event in tumorigenesis.

@en

P2093

Berx G

http://www.w3.org/2001/XMLSchema#string

Cleton-Jansen AM

http://www.w3.org/2001/XMLSchema#string

Cornelisse CJ

http://www.w3.org/2001/XMLSchema#string

Peterse JL

http://www.w3.org/2001/XMLSchema#string

Vos CB

http://www.w3.org/2001/XMLSchema#string

de Leeuw WJ

http://www.w3.org/2001/XMLSchema#string

ter Haar NT

http://www.w3.org/2001/XMLSchema#string

van Roy F

http://www.w3.org/2001/XMLSchema#string

P2860

E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers

Cadherin cell adhesion receptors as a morphogenetic regulator

Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.

E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain.

Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma

Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas

Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples.

Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.

Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast.

P2888

P304

1131-1133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1997.523

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Marc van de Vijver

P577

1997-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13865024

http://www.w3.org/2001/XMLSchema#string

P6179

1014479216

http://www.w3.org/2001/XMLSchema#string

P698

9365159

http://www.w3.org/2001/XMLSchema#string

P932

2228132

http://www.w3.org/2001/XMLSchema#string